

The Role of Cell Cycle Regulators in Normal and Malignant Cell Proliferation

Jinhwa Lee[†]

Department of Clinical Laboratory Science, Dongseo University, Busan 617-716, Korea

Cell proliferation is governed by precise and orderly process the regulation of which involves many different proteins. The key enzyme for cell growth and arrest is cyclin dependent kinases (cdks). In human cells, several cdks orchestrate four distinct cell cycle phases (M, G₁, S and G₂) and they sequentially operate in an order of cdc1, cdk4, cdk6 and cdk2. The regulatory components of cdks consist of cyclins and two family of cdk inhibitors, INK4 (inhibitors of cdk4) and KIP (kinase inhibitor protein). G₁ regulatory molecules for cdk mainly respond to environmental cues of mitogenic and anti-mitogenic stimuli and therefore influence activities of G₁ cdks, namely, cdk4/6 and cdk2. G₁ inhibitors include p21^{CIP} and p27^{KIP1}. Between them, p27^{KIP1} has attracted attentions of many researchers because of its characteristic regulatory features and diverse functions. Besides, the role of p27^{KIP1} in cancer development warrants further studies in the future. Therefore, this review will focus on the recent findings and especially on the complexity of regulatory mechanisms of p27^{KIP1}.

Key Words: Cell cycle, Arrest, cdk, p27^{KIP1}, Inhibitor

Binding of cell cycle inhibitors to cdk complexes

p27^{KIP1} was first identified as a key mediator of TGF- β induced G₁ arrest (Polyak, 1994; Reynisdottir et al., 1995). It was found that during the response to TGF- β , p27^{KIP1} moves out of cyclin D1-cdk4-p27^{KIP1} complexes and binds to inhibit cyclin E-cdk2, leading to G₁ arrest. Along with p21, p27^{KIP1} is a well-known inhibitor of cyclin E-cdk2 complexes. But in the case of cyclin D1-cdk4/6, p27^{KIP1} function in assembly and activation of the cdk complex and thus an activator rather than an inhibitor. p27^{KIP1} binding to cyclin D-cdk4/6 therefore may facilitate activation of cyclin E-cdk2 through sequestration of the inhibitory protein. The differential binding of p27^{KIP1} to the distinct early and late cdks during G₁ cell cycle, cdk2 and cdk4/6, can be attributed to the phosphorylation status of p27^{KIP1} (Ciarallo et al., 2002). Altered p27^{KIP1} phosphorylation may thus switch p27^{KIP1}

from cyclin E-cdk2 complexes to cyclin D-cdk complexes, allowing resistance to antiproliferative signals. The cyclin E-cdk2 inhibitory activity of p27^{KIP1} is maximal in G₀ and falls as cells move through G₁ into S phase. The cyclin D-cdk4/6 bound p27^{KIP1} is maximal during early G₁. On the stimuli of anti-mitogenic signalling, p27^{KIP1} dissociates from cdk4/6 complexes and accumulates in cyclin E-cdk2. The disrupted antiproliferative role of p27^{KIP1} by its preferred binding status to cyclin D-cdk4/6 over cyclinE-cdk2 may cause human malignancy (Fig. 1).

Posttranslational modification determines the function

p27^{KIP1} is a phosphoprotein and its phosphorylation is cell cycle regulated. Often phosphorylation is a signal for ubiquitination (Carrano, 1999; Montagnoli, 1999; Hara et al., 2001). p27^{KIP1} is phosphorylated on serine by Erk1. This finding raises the question of whether and how phosphorylation by kinases is involved in the process of p27^{KIP1} proteolysis. Cyclin E-cdk2 phosphorylates p27^{KIP1} on Thr187, phosphorylation site of which is required for ubiquitin-dependent phosphorylation. This specific proteolysis

*Received: 17 April, 2010 / Revised: 7 June, 2010

Accepted: 8 June, 2010

[†]Corresponding author: Jinhwa Lee, Department of Clinical Laboratory Science, Dongseo University, Busan 617-716, Korea.

Tel: 82-51-320-1799, Fax: 82-51-320-2721

e-mail: jinhwa2000@gdsu.dongseo.ac.kr




Fig. 1. Differential roles of cell cycle regulator p27^{KIP1} on cdk activities. As several cdk operate four distinct cell cycle phases (M, G₁, S and G₂), their regulatory components of cdk consist of cyclins and cdk inhibitors. The G₁ regulatory molecule, p27^{KIP1}, can help and block activities of cdk4 and cdk2, respectively. In early G₁, p27^{KIP1} can help assembly of cdk4 and cyclin D but the later G₁ p27^{KIP1} may become a bona fide cdk inhibitor toward the cyclin E-cdk2 complex. During this transition, p27^{KIP1} undergoes modification of phosphorylation or dephosphorylation by signalling kinases or phosphatases.

of p27^{KIP1} is involved in the pathway of activation of Cdks. Recent findings show that PKB can phosphorylate p27^{KIP1} directly without affecting stability of p27^{KIP1} on Threonine 157, which maps within the nuclear localization signal of p27^{KIP1} (Liang, 2002; Viglietto et al., 2002). The Akt-induced T157 phosphorylation causes retention of p27^{KIP1} in the cytoplasm, precluding p27^{KIP1}-induced G₁ arrest. Akt is also shown to down-regulate p27^{KIP1} transcription by phosphorylation-dependent inhibition of the Forkhead family of transcription factors. p27^{KIP1} needs to be transported into the nucleus to exert CDK inhibitory action, phosphorylation at Ser10 was recently reported to increase nuclear export of p27^{KIP1} through binding to CRM1. Therefore, several kinases regulate degradation and cytoplasmic localization of p27^{KIP1} through phosphorylation on various sites.

Localization by phosphorylation status

p27^{KIP1} phosphorylation by PKB impairs its nuclear import and leads to p27^{KIP1} accumulation in the cytoplasm. In human breast cancers, cytoplasmic mislocalization of

p27^{KIP1} is associated with PKB activation, loss of differentiation and poor patient outcome. Altered cell cycle regulation and defective checkpoint controls are a characteristic of cancer cells (Liang, 2002; Viglietto et al., 2002). Mislocalization of p27^{KIP1} can also lead to TGF- β resistance and gives a growth advantage during malignant cancer progression. Loss of the antiproliferative effects by p27^{KIP1} mislocalization in cytoplasm during TGF- β induced arrest signal can result in alterations in cell cycle controls. PI3K inhibitors such as wortmannin or LY294002, as well as overexpression of PTEN, result in upregulation of p27^{KIP1} and conversely, p27^{KIP1} is downregulated in the cells lacking PTEN (Kurose et al., 2001). The upregulation of p27^{KIP1} in response to decreased PIP₃ levels occurs by protein stabilization. P27^{KIP1} is destabilized by phosphorylation on T187 and subsequent recognition by ubiquitin-dependent proteasome machinery. Two kinases, CDK2 and Jab1, have been implicated in p27^{KIP1} destabilization and it was suggested that PKB might also be responsible for this destabilization. However, PKB is involved in mislocalization of p27^{KIP1} with its action of destabilization. PI3K inhibitors reduce the lifespan of cells (Fujita et al., 2002). Then, elevated p27^{KIP1} due to inhibition of PI3K signaling contributes to senescence. In the case of human tumors, p27^{KIP1} protein levels are often significantly diminished particularly in their more advanced stages. The downregulation of p27^{KIP1} in tumors occurs principally by protein destabilization, although it remains to be established whether this is a direct reflection of the balance between the activities of PTEN and PI3K. Relation of p27^{KIP1} mislocalization to cancer has been a focus and the biochemical pathways responsible for p27^{KIP1} cytosolic accumulation are under extensive investigations.

Deregulation in cancer

In many cancers, accelerated proteolysis causes reduced p27^{KIP1} protein. Less often, primary tumours may exhibit strong cytoplasmic p27^{KIP1} expression. Cytoplasmic p27^{KIP1} has been observed in some advanced cancer-derived cell lines. Thus, some cancers may express a stable but inactivated p27^{KIP1}. Mechanisms of mitogenic of anti-

mitogenic signalling pathways alter p27^{KIP1} inhibitor function are a focus in the field. Ras activation can lead to activation of PKB. PKB can increase cyclin D1 levels and down-regulate p27^{KIP1} expression. Thus, activation of the PI3K/PKB pathway may play a key role in loss of responsiveness to antiproliferative signals and cancer progression *in vivo* at least in part through impaired p27^{KIP1} localization and function. PKB mediates resistance to IL-6 or TGF-mediated G₁ arrest (Yue, 1999; Hideshima et al., 2001). The balance between PTEN and PI3K activities controls the levels of PIP₃, which serves as anchor site for proteins containing the pleckstrin-homology (PH) domain. The downstream target is the PH-containing Ser/Thr-kinases PDK-1 and PKB. Loss of PTEN occurs in a variety of human cancers and, its inactivation can lead to loss of cell cycle regulation (Li and Sun, 1998). PI3-kinase has many components and mutations in those components can cause dangerous human cancers. In c-Myc or MAPK activated cancer-derived lines, cyclin D1-cdk4/6 complexes sequester p27^{KIP1}, the cyclin E-cdk2-inhibitory action of p27^{KIP1} is impaired. c-Myc inhibits p15 induction by TGF-β and may also induce a factor that inactivates p27^{KIP1} (Sandhu, 2000; Gstaiger et al., 2001). Up to 50% of human cancers show loss of p27^{KIP1} through accelerated p27^{KIP1} proteolysis. In certain primary tumors, p27^{KIP1} is mislocalized to the cytoplasm away from nuclear targets and PKB activation might be responsible. A link between Ras and the cdk inhibitor p27^{KIP1}, where Ras causes down-regulation of p27^{KIP1} expression, has also been observed in a variety of cell types (Sheng et al., 2001). Down regulation of p27^{KIP1} levels in response to mitogenic stimuli in cancers are via a Ras-dependent mechanism. Mitogen activation of Ras and Ras-mediated downregulation of p27^{KIP1} in late G₁ involves both suppression of protein synthesis and enhancement of protein degradation in NIH 3T3 cells. Inhibition of PI3K, but not Erk, was found to block growth factor-induced downregulation of p27^{KIP1}. Ras also regulates p27^{KIP1} function by modulating its association with different cdk-cyclin complexes. There is a report that induction of activated MEK does not cause downregulation of p27^{KIP1} while it promotes the sequestration of p27^{KIP1} by cyclin D1 (Cheng et al., 1998). Another example is that the inducible

activation of estrogen receptor fusion proteins of Raf-1 or MEK1 caused downregulation of p27^{KIP1} protein levels in NIH 3T3 cells (Villalonga et al., 2000). Both PKB and Erk can phosphorylate p27^{KIP1} and phosphorylated p27^{KIP1} is impaired in binding to cdk2 (Lee et al., 2009).

Acknowledgements

This work was supported by grants from the Korean Government (MEST, No.20090091346) and 2010 supporting grants for research science development from Dongseo University.

REFERENCES

- Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. *Nat Cell Biol.* 1999. 1: 193-199.
- Cheng M, Sexl V, Sherr CJ, Roussel MF. Assembly of cyclin D-dependent kinase and titration of p27^{KIP1} regulated by mitogen-activated protein kinase kinase (MEK1). *Proc Natl Acad Sci U S A.* 1998. 95: 1091-1096.
- Ciarallo S, Subramaniam V, Hung W, Lee JH, Kotchetkov R, Sandhu C, Milic A, Slingerland JM. Altered p27(KIP1) phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor beta-mediated G(1) arrest. *Mol Cell Biol.* 2002. 22: 2993-3002.
- Fujita N, Sato S, Katayama K, Tsuruo. Akt-dependent phosphorylation of p27^{KIP1} promotes binding to 14-3-3 and cytoplasmic localization. *T. J Biol Chem.* 2002. 277: 28706-28713.
- Hara T, Kamura T, Nakayama K, Oshikawa K, Hatakeyama S, Nakayama K. Degradation of p27(KIP1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. *J Biol Chem.* 2001. 276: 48937-48943.
- Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek. Skp2 is oncogenic and overexpressed in human cancers. *W. Proc Natl Acad Sci U S A.* 2001. 98: 5043-5048.
- Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. *Oncogene* 2001. 20: 5991-6000.
- Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. *Eng C.*

- Am J Pathol . 2001. 158: 2097-2106.
- Lee J, Kim SS. The function of p27^{KIP1} during tumor development. *Exp Mol Med*. 2009. 41: 765-771.
- Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G₁ cell cycle arrest in human glioblastoma cells. *Proc Natl Acad Sci U S A*. 1998. 95: 15406-15411.
- Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G₁ arrest. *Nat Med*. 2002. 8: 1153-1160.
- Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. *Genes Dev*. 1999. 13: 1181-1189.
- Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. p27^{KIP1}, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. *Genes Dev*. 1994. 8: 9-22.
- Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. *Genes Dev*. 1995. 9: 1831-1845.
- Sandhu C, Slingerland J. Deregulation of the cell cycle in cancer. *Cancer Detect Prev*. 2000. 24: 107-118.
- Sheng H, Shao J, DuBois RN. Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells. *J Biol Chem*. 2001. 276: 14498-144504.
- Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tschlis P, Bellacosa A, Fusco A, Santoro M. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(KIP1) 120by PKB/Akt-mediated phosphorylation in breast cancer. *Nat Med*. 2002. 8: 1136-1144.
- Villalonga P, Rius E, Bachs O, Agell N. [Lys61]N-Ras is able to induce full activation and nuclear accumulation of Cdk4 in NIH3T3 cells. *Oncogene* 2000. 19: 690-699.
- Yue J, Frey RS, Mulder KM. Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGF beta. *Oncogene* 1999. 18: 2033-2037.
-